Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocad Joint Stock CofiledCriticalBiocad Joint Stock Co
Priority claimed from PCT/RU2018/050089external-prioritypatent/WO2019031990A1/en
Publication of MA48238A1publicationCriticalpatent/MA48238A1/en
Publication of MA48238B1publicationCriticalpatent/MA48238B1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
La présente invention concerne de nouveaux composés ayant la formule (i) ou leur sel pharmaceutiquement acceptable ou leur stéréoisomère possédant les propriétés de l'inhibiteur cdk8/19, une composition pharmaceutique contenant ces composés et leur utilisation en tant que préparations médicamenteuses pour traiter différentes maladies ou troubles.The present invention relates to novel compounds having the formula (i) or their pharmaceutically acceptable salt or their stereoisomer having the properties of the cdk8 / 19 inhibitor, a pharmaceutical composition containing these compounds and their use as medicinal preparations for treating various diseases. or troubles.
MA48238A2017-08-072018-07-30
New heterocyclic compounds as cdk8/19 inhibitors
MA48238B1
(en)
N- [4-fluoro-5 - [[(2s, 4s) -2-methyl-4 - [(5-methyl-1,2,4-oxadiazol-3-yl) methoxy] -1-piperidyl] methyl] thiazol-2-yl] acetamide used as an inhibitor of yoga